Navigation Links
JCI early table of contents for Aug. 8, 2013
Date:8/9/2013

Engineered rice protects against rotavirus

For children and immune compromised adults in developing countries, diarrheal disease induced by rotavirus can be life threatening. Current rotaviral vaccines are highly effective in the Western world, but are not as effective in developing countries. Additionally, these vaccines are not appropriate for use outside of a very narrow age window or in immune compromised individuals. In the current issue of the Journal of Clinical Investigation Yoshikazu Yuki and colleagues at the University of Tokyo report the development of a strain of rice that produces a rotavirus-specific antibody. Both normal and immune deficient mice fed the engineered rice were protected against rotavirus. The researchers also report that the rice maintains its efficacy even after long-term storage and heat exposure. This study provides a low cost, efficient strategy for prevention of rotavirus infection.

TITLE: Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection

AUTHOR CONTACT: Daisuke Tokuhara
The Institute of Medical Science, The University of Tokyo, Tokyo, UNK, JPN
Phone: 81-3-5449-5271; Fax: 81-3-5449-5411; E-mail: tokuhara@ims.u-tokyo.ac.jp

View this article at: http://www.jci.org/articles/view/70266?key=de80321a713532149b56


Tumor microenvironment allows cancer cells to hide from the immune system

Cancer progression is aided by the ability of tumors to evade recognition by the immune system. In this issue of the Journal of Clinical Investigation, Gerard Blobe and colleagues at Duke University identify a mechanism by which tumors evade detection. Using mouse models of breast cancer and melanoma, they show that loss of the Type III TGF-β receptor (TGFBR3) in tumors promotes cancer progression by altering signaling in tumor-associated immune cells. This study supports the use of TGF-β inhibitors to enhance the efficacy of therapies that promote immune-mediated elimination of tumor cells.

TITLE: Type III TGF-β receptor downregulation generates and immunotolerant tumor microenvironment

AUTHOR CONTACT: Gerard C. Blobe
Duke University, Durham, NC, USA
Phone: (919) 668-1352; Fax: (919) 681-6906; E-mail: blobe001@mc.duke.edu

View this article at: http://www.jci.org/articles/view/65745?key=f673123b974c4089ed3b


ALSO IN THIS ISSUE

TITLE: Retinoids activate the irritant receptor TRPV1 and produce sensory hypersensitivity

AUTHOR CONTACT: Hongzhen Hu
University of Texas Health Science at Houston, Houston, TX, USA
Phone: 713-500-7525; E-mail: Hongzhen.Hu@uth.tmc.edu

View this article at: http://www.jci.org/articles/view/66413?key=07980efc5faef311fc46

TITLE: Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B

AUTHOR CONTACT: Jody Baron
University of California, San Francisco, San Francsico, CA, USA
Phone: 415 476 5728; Fax: 415 476 0659; E-mail: jody.baron@ucsf.edu

View this article at: http://www.jci.org/articles/view/68182?key=4813eaa63d2ce5b8fb76

TITLE: Increased Fanconi C expression contributes to the emergency granulopoiesis response

AUTHOR CONTACT: Elizabeth Eklund
Northwestern University and Jesse Brown VHA Medical Center, Chicago, IL, USA
Phone: 312 503 3207; Fax: 312 908 5717; E-mail: e-eklund@northwestern.edu

View this article at: http://www.jci.org/articles/view/69032?key=1ae6052432e2d7e84f1e

TITLE: Nanoparticle-based flow virometry for the analysis of individual virions

AUTHOR CONTACT: Jean-Charles Grivel
Eunice Kennedy Shriver National Institute of Child Health & Human Development, Bethesda, MD, USA
Phone: 301 496 1298; Fax: 301 480 0857; E-mail: mailto:grivelj@mail.nih.gov

View this article at: http://www.jci.org/articles/view/67042?key=a318cc3a6f46bf3f4469


'/>"/>

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Related biology technology :

1. Pearly Whites Laser Dentistry Launches Ground Breaking Cavity Prevention Program that Can Lower Decay Rates by 74%
2. RiboMed and Austrian Institute of Technology Partner on Epigenetic Tests for Early Lung Cancer Detection, Sub-typing and Drug Response
3. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
4. Adult cells transformed into early-stage nerve cells, bypassing the pluripotent stem cell stage
5. Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies
6. Finally, the need of nearly every woman wanting to look more beautiful is fulfilled with Crisalix, the first online direct-to-consumer 3D imaging using standard pictures
7. Bed Bugs Get Family Throwing Nearly All Their Possessions, My Cleaning Offers Help With Complimentary Samples of Non-Pesticide Bed Bug Bully
8. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
9. JCI early table of contents for March 25, 2013
10. The Elsevier Foundation, TWAS, and OWSD Honor Early Career Women Scientists in Developing Countries at the Annual AAAS Meeting
11. Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
(Date:3/18/2016)... 2016 --> --> ... Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & ... the border security market and the continuing migration crisis in ... Europe has led visiongain to publish this unique ... --> defence & security companies in the border ...
Breaking Biology News(10 mins):